Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863059 | 1.00 | L3MBTL1 (0.31) | L3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3595043 | 0.82 | SLC6A2 (0.34) | L3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3595787 | 0.82 | SLC6A2 (0.34) | L3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1859646 | 0.79 | SLC6A2 (0.34) | L3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1863285 | 0.79 | SLC6A2 (0.34) | L3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1860870 | 0.78 | CHRNB2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL972233 | 0.77 | — | — | |
| SCHEMBL972229 | 0.77 | — | — | |
| SCHEMBL1865578 | 0.76 | EPHX1 (0.36) | L3MBTL1 | |
| SCHEMBL1862456 | 0.74 | EPHX1 (0.34) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | L3MBTL1 3595/4885SLC6A2 3389/4885SLC6A4 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.